Business Context and Reporting Period
Company: West Pharmaceutical Services, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 9, 2025
Event Date: March 7, 2025 (Departure of Executive Officer)
Key Financial Metrics
This filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It specifically details the financial terms of a severance agreement for a departing executive.
| Benefit Component | Value |
|---|---|
| Salary Continuation | 1 year at $489,500 |
| 2025 Pro-rated Incentive Payment | $57,526 |
| Outplacement Services | Up to $15,000 |
| Welfare Benefits | Continued at active employee rate |
Material Changes
- Executive Departure: Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer, departed effective March 7, 2025.
- Compensatory Arrangement: The Company entered into a Separation Agreement and Release with Ms. Reiss-Clark, contingent upon the execution of a release and compliance with covenants.
Outlook, Risks, and Unusual Items
Management Commentary: The departure was announced as part of standard personnel changes. The agreement includes standard noncompetition, nonsolicitation, and nondisparagement provisions.
Risks and Contingencies: The severance benefits are contingent upon Ms. Reiss-Clark executing a release of claims against the Company and its affiliates. In exchange, she has agreed not to pursue litigation and to cooperate with the Company as needed.
Investor Verification Checklist
- Verify the total cash impact of the severance package ($489,500 salary + $57,526 incentive + up to $15,000 outplacement).
- Confirm the status of the release of claims and whether the severance payment has been finalized.
- Review the Company's succession plan for the Chief Commercial Officer role, as this information is not included in this filing.
- Check subsequent filings for any impact on the Company's operating expenses or goodwill related to this executive departure.